Sept. 23, 2007 — The U.S.
Food and Drug Governance (FDA) has approved first-time generic wine
formulations of 10 µg (base)/mL liothyronine sodium insertion in 1-mL
vials for the care of myxedema coma/precoma; 1 g/50 mL and 2 g/50 mL
ceftriaxone shot packaged in coltsfoot single-dose charge plate
containers for the artistic style of infections caused by susceptible
micro-organisms and for prophylaxis of postsurgical infections; and 30,
60, and 180 mg fexofenadine HCl tablets for the discussion of seasonal
allergic rhinitis and chronic idiopathic urticaria in patients aged six
eld and older.
On
Aug. 17, the FDA approved a first-time generic wine conceptualization
of 10 µg [base]/mL liothyronine sodium introduction in 1-mL vials (made
by Pharmaforce, Inc.; form name Triostat, made by Designer Pharma, Inc.)
Liothyronine sodium solution is indicated for the communicating of myxedema coma/precoma.
It can be used in patients allergic to desiccated thyroid or thyroid excerption derived from pork or beef.
On
Aug. 23, the FDA approved first-time merchandise formulations of 1 g/50
mL and 2 g/50 mL ceftriaxone injectant packaged in collection
single-dose revolving credit containers (made by Baxter Healthcare
Corp.; firewood name Rocephin, made by Hoffman-LaRoche).
Ceftriaxone
insertion is indicated for the care of infections caused by susceptible
micro-organisms, including skin and skin social organization
infections, acute bacterial otitis media, lower respiratory piece of
ground infections, urinary piece of land infections, uncomplicated
gonorrhea, pelvic inflammatory disease, bacterial septicemia, bone and
roast infections, intra-abdominal infections, and meningitis.
It is also indicated for the prophylaxis of postsurgical infections.
On
Aug. 31, the FDA approved first-time wine formulations of 30, 60, and
180 mg fexofenadine HCl tablets (made by Barr Laboratories, Inc.; arm
name Allegra, made by Aventis Pharmaceuticals, Inc.).
Fexofenadine
tablets are indicated for the equal of symptoms associated with
seasonal allergic rhinitis in adults and children aged six eld and
older.
Symptoms treated effectively in clinical studies included sneezing,
rhinorrhea, itchy nose/palate/throat, and itchy/watery/red eyes.
Fexofenadine
is also indicated for the aid of uncomplicated skin manifestations of
chronic idiopathic urticaria in adults and children aged six eld and
older.
In clinical studies, fexofenadine significantly reduced pruritus and
signal of wheals.